LPCAT1

Across TCGA pan-cancer cohorts, LPCAT1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LPCAT1 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LPCAT1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated LPCAT1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

UCEC, BRCA, and STAD are the cancer types where LPCAT1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.958	0.827	.021	20	view →
BRCA	OS	Median	III,IV	0.001	0.907	<.001	16	view →
STAD	OS	Median	All	0.225	0.734	<.001	12	view →
SKCM	OS	Median	All	0.357	0.787	.005	6	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →
LUSC	DFS	Median	All	1.000	0.387	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LPCAT1–UCEC (DFS)

Open the UCEC breakdown →